Nandini Dey

PI3K‐AKT‐mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials

Pradip De, B. Leyland-Jones, P. De, 2017, Pharmacology & therapeutics.

MYC-xing it up with PIK3CA mutation and resistance to PI3K inhibitors: summit of two giants in breast cancers.

Pradip De, Brian Leyland-Jones, B. Leyland-Jones, 2015, American journal of cancer research.

Wnt signaling in triple negative breast cancer is associated with metastasis

Pradip De, G. Sledge, B. Leyland-Jones, 2013, BMC Cancer.

Mutation matters in precision medicine: A future to believe in.

Pradip De, Brian Leyland-Jones, B. Leyland-Jones, 2017, Cancer treatment reviews.

Triple Fluorescence staining to Evaluate Mechanism-based Apoptosis following Chemotherapeutic and Targeted Anti-cancer Drugs in Live Tumor Cells

Pradip De, Brian Leyland-Jones, B. Leyland-Jones, 2018, Scientific Reports.